Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

A man who could be facing the death penalty in the death of a Morrow County sheriff’s deputy had his second arraignment ...

The “March of Dissent” rally on Saturday was in response to the lack of abortion access in Texas among other concerns, an ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

At the Heart in Diabetes CME Conference, speakers highlighted four recent reports published in the Journal of the American ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.